App-Quantinova.ai

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Dexamethasone

Evaluation of Global Hemostasis Assays in Von Willebrand Disease Type 3 in Comparison with Mild to Moderate Hemophilia a

Sreya Punjadath Baby - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

folitixorin calcium

Emergent Large-Bore Central Venous Catheter Placement in Severely Thrombocytopenic Patients with Suspected Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Safe and Effective

Nicholas C.J. Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Rituximab in the Treatment of Refractory Heparin Induced Thrombocytopenia

Akshee Batra - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Methylprednisolone

Real World Outcomes of Therapeutic Anticoagulation Use in Moderate COVID-19 Infection in Hospitalised Patients

Katherine J. Creeper - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

Factors Associated with Thrombosis in Hospitalized COVID Patients

Girindra Ghanshyam Raval - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Fibrinogen (IV)

A Difficult Task: Determining Oral Anticoagulation Efficacy (OAC) in Patients with HIT Type II

Humza Malik - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Argatroban

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Tammuella Chrisentery-Singleton - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rFVIIa

Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease Inpatients: Systematic Review and Meta-Analysis

Rotem McNeil - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Arterial Thromboembolism in Cancer Patients Treated with Apixaban

Trine-Lise Larsen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

apixaban

Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Craig I. Coleman - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rivaroxaban

Assessing the Relationship between Thrombosis and Immune-Related Adverse Events in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors

Daniela Arango Isaza - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Pembrolizumab

Low Molecular Weight Heparin Anti-Factor Xa Level Monitoring in a Healthcare System

Natalie Quesep - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Heparin

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Erika Morsia - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Hemostatic Solution

Recurrent Venous Thromboembolism with Direct-Acting Oral Anticoagulants and Body Mass Index: A Single Institutional Study

Shiva Jashwanth Gaddam - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rivaroxaban

Ordering Patterns, Cost, and Utility of Factor V Leiden Testing in an Academic Medical Center

Tahani Atieh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Protein C

Achieving Therapeutic Anti-Xa Levels Using Rivaroxaban for Venous Thromboembolism in a Morbidly Obese Patient with a BMI >70

Swathi Prakash - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

rivaroxaban

Hemostatic Profile at Diagnosis in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of Cases from the Literature

Paul Thuan Tieu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Hemostatic Solution

Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Giovanni Manfredi Assanto - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

ASXL1 Is a Risk Factor for Thrombosis in Polycythemia Vera

Yuhui Zhang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Filters

7277 Abstracts